Thirty years ago this October, Merck & Co. vowed that it would immediately begin distributing the drug free of charge, to any country that requested it, “for as long as needed.” It was the final piece of the puzzle: an effective drug for a tragic and completely preventable disease. And we all lived happily ever after. Only… we didn’t.

Quick Read

A federal judge in Texas invalidated four key patents for the dry-eye treatment Restasis on Monday, dealing a blow to its manufacturer, Allergan, which had sought to protect its patents by transferring them to a Native American tribe

Quick Read

Who will pay for it? And how?

Quick Read

In a deal similar to the one that turned the tide against AIDS, manufacturers and charities will make chemotherapy drugs available in six poor countries at steep discounts

Quick Read

For the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible. The key to making the therapy work? One of medicine’s greatest villains: HIV

Quick Read

Drug companies and doctors have been accused of fueling the opioid crisis, but some question whether insurers have played a role, too

Quick Read

Although vaccines typically take years to produce, test, and license, US health officials had voiced confidence that Zika would not be a difficult target, and some predicted that a vaccine could be made and fully tested, ready for FDA assessment, within two to three years. Others predicted a licensed Zika vaccine could be available sometime in 2020

Quick Read

How to Protect a Drug Patent?

September 11, 2017

Sell it to a Native American Tribe. The drugmaker Allergan announced Friday that it had transferred its patents on a best-selling eye drug to the Saint Regis Mohawk Tribe in upstate New York — an unusual gambit to protect the drug from a patent dispute

Quick Read